Efficacy of agomelatine in generalized anxiety disorder: A randomized, double-blind, placebo-controlled study

Journal of Clinical Psychopharmacology

Volumn 28, Issue 5, 2008, Pages 561-566

  Stein, Dan J ^a,d   Ahokas, Antti A ^b   De Bodinat, Christian ^c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b L äak arikeskus Mehil ainen T öol o   (Finland)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; PLACEBO; ACETAMIDE DERIVATIVE; HYPNOTIC SEDATIVE AGENT; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; SEROTONIN 2C RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISABILITY; DIZZINESS; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WITHDRAWAL SYNDROME; ADOLESCENT; ANXIETY DISORDER; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL RATING SCALE;

ACETAMIDES; ADOLESCENT; ADULT; AGED; ANXIETY DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; RECEPTOR, SEROTONIN, 5-HT2C; TREATMENT OUTCOME;

EID: 58149129754     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318184ff5b     Document Type: Article

References (27)

1. Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003; 306:954-964.
2. Millan MJ, Brocco M, Gobert A, et al. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacologia. 2005;177:448-458.
3. Loiseau F, Le Bihan C, Hamon M, et al. Effects of melatonin and agomelatine in anxiety-related procedures in rats: interaction with diazepam. Eur Neuropsychopharmacol. 2006;16:417-428.
4. Papp ML, Litwa E, Gruca P, et al. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav Pharmacol. 2006;17:9-18.
5. Loo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol. 2002;17:239-247.
6. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. European neuropsychopharma- cology. Eur Neuropsychopharmacol. 2006;16:93-100.
7. Olié JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol. 2007;4:1-13.
8. Den Boer JA, Bosker FJ, Meesters Y. Clinical efficacy of agomelatine in depression: the evidence. Int Clin Psychopharmacol. 2006;21:S21-S24.
9. Dubocovich ML. Agomelatine targets a range of major depressive disorder symptoms. Curr Opin Investig Drugs. 2006;7:670-680.
10. Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on generalized anxiety disorder from the international consensus group on depression and anxiety. JClin Psychiatry. 2001;62:53-58.
11. Bandelow B, Zohar J, Hollander E, et al. WFSBP task force on treatment guidelines for anxiety, obsessive-compulsive and post- traumatic stress disorders. World federation of societies of biological psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World JBiol Psychiatry. 2002;3:171-199.
12. Allgulander C, Bandelow B, Hollander E, et al. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr. 2003;8:53-61.
13. Baldwin DS, Polkinghorn C. Evidence-based pharmacotherapy of Generalized Anxiety Disorder. Int Clin Psychopharmacol. 2005;8:293-302.
14. Kapczinski F, Lima MS, Souza JS, et al. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev. 2003;CD003592.
15. Montgomery SA, Kennedy SH, Burrows GD, et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol. 2004;19:271-280.
16. Kessler RC. The epidemiology of pure and comorbid generalized anxiety disorder. A review and evaluation of recent research. Acta Psychiatr Scand. 2000;406:7-13.
17. Stein DJ. Comorbidity in generalized anxiety disorder: impact and implications. JClin Psychiatry. 2001;62:29-34.
18. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation ofa structured diagnostic psychiatric interview for DSM-IVand ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33.
19. Hamilton M. A rating scale for anxiety. J Neurol Neurosurg Psychiatr. 1959;23:56-62.
20. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361-370.
21. Montgomery SA and Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
22. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare Publication (ADM). Rockville, MD: National Institute of Mental Health, 1976;76-338.
23. Stein DJ. Generalized anxiety disorder: rethinking diagnosis and rating. CNSSpectr. 2005;10:930-934.
24. Parrott AC, Hindmarch I. The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations - a review. Psychopharmacologia. 1980;71:173-179.
25. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11:89-95.
26. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reup- take inhibitor discontinuation syndrome: a randomized clinical trial. Biological Psychiatry. 1998;44:77-87.
27. CPMP/EWP/4284/02, 20th Guideline on the clinical investigation of medicinal products indicated for Generalized Anxiety Disorder, The European Medicines Agency, January 2005.